Startups

Precision Neuroscience

New York, New York · New York, United States

Private neural-interface company developing Layer 7 cortical-surface arrays. Its 2025 FDA clearance covers temporary use up to 30 days; a permanent paralysis-treatment BCI remains investigational. Company reported $430M cumulative capital in September 2026.

Founded 2021

Team

John DonoghueScientific Advisor, appointed July 2026

Ben RapoportCo-Founder & Chief Science Officer

Benjamin Rapoportco-founder and Chief Science Officer

Brian OtisHistorical CTO (confirmed December 2024)

Craig MermelChief AI and Data Officer

Demetrios PapageorgiouFounding team member (2021)

Jayme StraussChief Clinical Officer

Joel GreengrassChief People Officer

Mark HettickCo-founder

Michael Magerco-founder and CEO

Mike KaswanCFO

Nate PletcherCTO

Peter SocarrasSenior VP, General Counsel

Vanessa TolosaSenior VP, R&D Operations

Investments

$250M2026-09-24	Pershing Square Capital Management, Ackman Oxman Institute, Duquesne Family Office, B Capital, ARK, The Invus Group, LLC, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, JSL Health Capital
$—2025-11-05	SCI Ventures
$102M2024-12-16	General Equity Holdings, B Capital, Duquesne Family Office, Steadview Capital
$41M2023-01-25	Forepont Capital Partners, Mubadala Capital, Draper Associates, Alumni Ventures, re.Mind Capital, Steadview Capital, B Capital
$12M2021-05-25	Steadview Capital, B Capital, Forepont Capital Partners

team@apexlogos.ai11 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: PrecisionNeuroscience. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 2/2 reconcile individual transactions before import. Read-only `Org` lookup found the following records. The snapshot below records existing claims, **not verification of those claims**.
team@apexlogos.ai11 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: PrecisionNeuroscience. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/2 # Precision Neuroscience Research date: **2026-10-06**. Review material only; no adex data was modified. All linked sources and HTML image references were accessed on this date. ## Identity and operating status **Precision Neuroscience Corporation**, private BCI company founded 2021 and headquartered in New York. Layer 7 is an ultra-thin cortical-surface electrode array that records without penetrating cortex. Active clinical/research development. [Official technology/leadership](https://www.precisionneuro.io/our-vision) FDA clearance for the Layer 7 Cortical Interface in 2025 permits **temporary use up to 30 days** for brain-surface recording/mapping/stimulation; it does not establish approval of a permanently implanted paralysis treatment. [Company clearance announcement](https://www.precisionneuro.io/articles/company-news/precision-neuroscience-receives-fda-clearance-for-high-resolution-cortical-electrode-array) ## Audit of pasted BCI.INTEL entry | Pasted claim | Assessment | |---|---| | NYC HQ; Michael Mager CEO | Confirmed. | | $183M total | Stale/unreconciled: Dec 2024 official total was $155M; **2026-09-24 company release states $430M** following $250M Series D. | | Layer 7 | Confirmed; temporary FDA-cleared electrode differs from investigational full BCI treatment. | | ACTIVE | Confirmed by current financing, leadership and clinical activity. | | Ticker: FDA.Brkthru | Historical designation supported; clearance status is now more specific and should be recorded separately. | ## Company profile image Company profile image: [Official OG image](https://cdn.sanity.io/images/883wn8od/production/27b30ec3135c38d300a7ad288ad4d71b142bdcd1-1200x630.png?fm=webp&w=1200&q=75) from official site `<meta property="og:image">`; this is a share card, not guaranteed a square logo. Current executive headshots extracted by exact `<img alt="Person Name">` from [official leadership](https://www.precisionneuro.io/our-vision). ## Founders and public team | Person | Role / relationship | Profile and role evidence | Direct profile image URL | |---|---|---|---| | Michael Mager | Current co-founder and CEO | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/8da07aa215bc857c2b93a655f35d645e259bf5d5-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Craig Mermel | Current Chief AI and Data Officer | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/5a5721827f83d9045b42f1a2a7b855a7321a4840-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Benjamin Rapoport | Current co-founder and Chief Science Officer | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/6bcade5ccccb4c00f95aae00bc585e320576361d-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Mike Kaswan | Current CFO | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/63faa6a9c6829a762dd3d598a744fb33f597a346-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Jayme Strauss | Current Chief Clinical Officer | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/9d0aaeccc191b04cd3cccb2698aacf93a0ee5463-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Joel Greengrass | Current Chief People Officer | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/6e9f0cf65f17a66bccda3698cc81d9bbc750e7f5-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Nate Pletcher | Current CTO | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/46e0daf143577ef4a659116dc3ba8275b25111a2-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Vanessa Tolosa | Current Senior VP, R&D Operations; former Neuralink co-founder | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/6cf6f40561c79910849720a7282b6561789fd5b4-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Peter Socarras | Current Senior VP, General Counsel | [Official leadership card](https://www.precisionneuro.io/our-vision) | [PFP](https://cdn.sanity.io/images/883wn8od/production/d4df5ed3c6552df4b576acc7db8b0561eadcb892-1304x1500.jpg?fm=webp&w=1304&q=75&h=1505&fit=crop) | | Mark Hettick | 2021 founding team; current role not verified | [Company-issued founding release](https://www.prnewswire.com/news-releases/precision-neuroscience-raises-12m-to-develop-next-generation-brain-computer-interface-technology-301298952.html) | Unavailable; not shown in current leadership grid | | Demetrios Papageorgiou | 2021 founding team; current role not verified | [Company-issued founding release](https://www.prnewswire.com/news-releases/precision-neuroscience-raises-12m-to-develop-next-generation-brain-computer-interface-technology-301298952.html) | Unavailable; not shown in current leadership grid | | Brian Otis | CTO named in Dec 2024; superseded by current grid listing Nate Pletcher | [2024 company financing release](https://www.globenewswire.com/news-release/2024/12/16/2997364/0/en/Precision-Neuroscience-Raises-102-Million-to-Advance-AI-Powered-Brain-Implant.html) | Unavailable in current grid | | John Donoghue | Scientific Advisor, appointed July 2026; not employee inferred | [2026 company financing release](https://www.globenewswire.com/news-release/2026/09/24/3368254/0/en/precision-neuroscience-closes-oversubscribed-250m-series-d-led-by-pershing-square-inc-the-ackman-oxman-institute-and-a-leading-life-sciences-investment-fund.html) | [BrainGate portrait](https://www.braingate.org/wp-content/uploads/2015/12/Donoghue-150x150.jpg) | ## Investments and financing | Announced date | Round/type | Amount (USD) | Lead(s) | Other named participants | Evidence | |---|---|---:|---|---|---| | 2021-05-25 | Series A | $12M | Steadview Capital; B Capital Ascent Team | Forepont Capital Partners | [Company-issued PR Newswire](https://www.prnewswire.com/news-releases/precision-neuroscience-raises-12m-to-develop-next-generation-brain-computer-interface-technology-301298952.html) | | 2023-01-25 | Series B | $41M | Forepont Capital Partners | Mubadala Capital; Draper Associates; Alumni Ventures; re.Mind Capital; Steadview Capital; B Capital | [Company-issued GlobeNewswire](https://www.globenewswire.com/news-release/2023/01/25/2595114/0/en/Precision-Neuroscience-Raises-41-Million-to-Build-and-Scale-the-Next-Generation-of-Treatments-for-Neurological-Illnesses.html) | | 2024-12-16 | Series C | $102M | General Equity Holdings | B Capital; Duquesne Family Office; Steadview Capital | [Company-issued GlobeNewswire](https://www.globenewswire.com/news-release/2024/12/16/2997364/0/en/Precision-Neuroscience-Raises-102-Million-to-Advance-AI-Powered-Brain-Implant.html) | | 2025-11 | Strategic SCI Ventures investment | Undisclosed | SCI Ventures | No cheque-level co-investors asserted | [Company partnership announcement](https://www.precisionneuro.io/articles/company-news/precision-neuroscience-and-sci-ventures-partner-to-bring-brain-computer-interfaces-to-people-living-with-paralysis) | | 2026-09-24 | Series D | $250M | Pershing Square Inc.; Ackman Oxman Institute; undisclosed life-sciences investment fund | Duquesne Family Office; B Capital; ARK Invest; Invus; Mubadala Capital; Mirae Asset Capital; Korea Investment Partners; Hitachi Ventures; JSL Health Capital; others unnamed | [Company-issued financing release](https://www.globenewswire.com/news-release/2026/09/24/3368254/0/en/precision-neuroscience-closes-oversubscribed-250m-series-d-led-by-pershing-square-inc-the-ackman-oxman-institute-and-a-leading-life-sciences-investment-fund.html) | Latest company-reported lifetime total is $430M. Four disclosed round headline amounts sum to $405M; the **$25M difference is not a new inferred round** and may involve undisclosed financing/round extensions. SCI Ventures amount is not public in the cited announcement. Texas manufacturing facility purchase is an acquisition, not investment capital raised. Medtronic agreement is a commercial partnership; no investment or acquisition amount should be inferred. No verified grant/debt close is entered. ## Existing adex match and review decision Already present as `PrecisionNeuroscience`. Update existing profile after review, especially financing and current CTO; do not duplicate. Preserve the distinction between temporary electrode clearance and a commercial chronic BCI. Pasted total should be replaced only with explicitly dated company-reported $430M;
team@apexlogos.ai22 days ago
COMPETITION